Khiron is the exclusive Latin American
supplier to Project Twenty21, a leading UK registry study enrolling
up to 20,000 patients by the end of 2021, to create the largest
body of evidence in Europe for the
effectiveness and tolerability of medical cannabis
- First import of EU GMP medical cannabis products is
complete
- Khiron branded products available to participating UK doctors,
with first prescriptions now received
- Khiron has secured a strategic partnership with an EU GMP
fulfilment partner which can deliver patient prescriptions to their
homes
- UK medical cannabis clinics and doctors have received
regulatory approval to conduct teleconsultations with patients, a
new milestone in opening up patient access
- Approximately 1.4m people in
Great Britain are using "street
cannabis" to treat medically diagnosed, chronic health conditions
(source: YouGov)
- By 2024, the UK medical cannabis market is predicted to be
worth nearly £1bn, servicing nearly 340,000 active patients
(source: Prohibition Partners)
TORONTO, May 6, 2020 /CNW/ - Khiron Life Sciences
Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQX:
KHRNF), (Frankfurt: A2JMZC), a
vertically integrated cannabis leader with core operations in
Latin America and Europe, today announced the receipt of its
first medical cannabis prescriptions for patients participating in
Project Twenty21 in the United
Kingdom (UK). Khiron branded EU GMP medical cannabis is now
available for prescription from doctors and clinics participating
in Project Twenty21, Europe's
largest study of the effectiveness and tolerability of medical
cannabis.
Khiron has been actively preparing to supply Project Twenty21
since first announcing its participation in November 2019. The supply of EU GMP medical
cannabis is fully supported by the Company's global medical
education team, led by Dr. Maria Fernanda
Arboleda, International Director for Medical Services.
Khiron will leverage educational materials and key learnings from
the Company's Colombian cannabis experience in making therapeutic
recommendations for Project Twenty21.
Leading the project, Professor David
Nutt from the UK's leading independent scientific body Drug
Science commented: "Khiron's assistance in delivering Project
Twenty21 will expand the formulary significantly. Our shared
vision, accelerating access of medical cannabis to patients who
need it the most, will be greatly enhanced by the support provided
by the Khiron team."
Tejinder Virk, President of
Khiron Europe, commented: "The receipt of our first prescriptions
in the UK is a testament to Khiron's regulatory strengths and
globally diversified supply chain strategy. We have the flexibility
to source medical cannabis products from multiple countries, with
an aim to optimize for quality, speed and economics. The
implementation of virtual consultations in the UK and mail order
fulfilment are also huge milestones, which remove friction for
patients and help to drive positive health outcomes."
Khiron is the exclusive LatAm supplier to Project Twenty21,
Europe's first and largest
national medical cannabis registry study in November 2019. Project Twenty21 aims to enrol
20,000 patients by the end of 2021, creating the largest body of
evidence for the effectiveness and tolerability of medical cannabis
– with an aim to demonstrate to policymakers that medical cannabis
should be as widely available, and affordable, as other approved
medicines for patients who would benefit from them.
About Khiron Life Sciences Corp.
Khiron Life Sciences
Corp. is the dominant integrated medical cannabis company in
Latin America. Khiron has core
operations in Latin America, along
with activity in North America and
Europe, and is licensed in
Colombia for the cultivation,
production, domestic distribution, and international export of both
tetrahydrocannabinol (THC) and cannabidiol (CBD) medical cannabis.
The Company delivers best in class regulatory compliance, has the
first approved line of CBD cosmetic products on shelf
in Colombia, and is fully authorized to manufacture high- and
low-THC medical cannabis, and to fill prescriptions for low-THC
medical cannabis in the country.
With a focused regional strategy and patient oriented
approach, the Company combines global scientific expertise,
agricultural advantages, branded product market entrance
experience and education to drive prescription and brand
loyalty to address priority medical conditions such as chronic
pain, epilepsy, depression and anxiety in the Latin American
market of over 620 million people. The Company is led by Co-founder
and Chief Executive Officer, Alvaro
Torres, together with an experienced executive team,
and a knowledgeable Board of Directors that includes former
President of Mexico, Vicente Fox.
Visit Khiron online at www.khiron.ca and on Instagram
@khironlife
Cautionary Notes
Market and Industry Data
This press release includes market and industry data and
forecasts that were obtained from third-party sources, industry
publications and publicly available information. Third-party
sources generally state that the information contained therein has
been obtained from sources believed to be reliable, but there can
be no assurance as to the accuracy or completeness of included
information. Although management believes it to be reliable, Khiron
has not independently verified any of the data from third-party
sources referred to in this presentation, or analyzed or verified
the underlying studies or surveys relied upon or referred to by
such sources, or ascertained the underlying economic assumptions
relied upon by such sources.
Forward-Looking Statements
This press release may contain certain "forward-looking
information" and "forward-looking statements" within the meaning of
applicable securities legislation. All information contained herein
that is not historical in nature may constitute forward-looking
information. Khiron undertakes no obligation to comment analyses,
expectations or statements made by third-parties in respect of
Khiron, its securities, or financial or operating results (as
applicable). Although Khiron believes that the expectations
reflected in forward-looking statements in this press release are
reasonable, such forward-looking statement has been based on
expectations, factors and assumptions concerning future events
which may prove to be inaccurate and are subject to numerous risks
and uncertainties, certain of which are beyond Khiron's control,
including the risk factors discussed in Khiron's Annual Information
Form which is available on Khiron's SEDAR profile
at www.sedar.com. The forward-looking information contained in
this press release is expressly qualified by this cautionary
statement and are made as of the date hereof. Khiron disclaims any
intention and has no obligation or responsibility, except as
required by law, to update or revise any forward-looking
information, whether as a result of new information, future events
or otherwise.
Neither the TSXV nor its Regulation Services Provider (as
that term is defined in the policies of the TSXV) accepts
responsibility for the adequacy or accuracy of this press
release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/khiron-receives-first-medical-cannabis-prescriptions-for-uk-patients-participating-in-project-twenty21-301053537.html
SOURCE Khiron Life Sciences Corp.